Paper Details

  1. Home
  2. Paper Details

Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.

Author: AbbasZaigham, AbidShahab, HamidSaeed, IslamMuhammad, JafriWasim, MumtazKhalid, ShahHasnain Ali

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

L-ornithine-L-aspartate (LOLA) was safe and effective as an adjuvant therapy for cirrhotic patients with hepatic encephalopathy (HE), particularly those with advanced HE (grade II and above). LOLA treatment resulted in faster improvement and a shorter hospital stay compared to placebo.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE). STUDY DESIGN: Randomized placebo controlled study. PLACE AND DURATION OF STUDY: The Aga Khan University Hospital, Karachi in the year 2003-2004. MET...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/22078345

データ提供：米国国立医学図書館（NLM）

The efficacy of L-ornithine-L-aspartate in treating hepatic encephalopathy

Hepatic encephalopathy is a serious complication of liver disease that can lead to confusion, disorientation, and even coma. This study investigates the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy for patients with hepatic encephalopathy. It's like exploring the desert of liver disease, seeking a treatment to alleviate the symptoms and improve the quality of life for patients.

LOLA: A potential oasis in the desert of liver disease

The researchers conducted a randomized placebo-controlled study to evaluate the effectiveness of LOLA in patients with hepatic encephalopathy. They discovered that LOLA was associated with a significant improvement in hepatic encephalopathy, leading to a shorter hospital stay and a faster recovery. It's like finding a well-maintained oasis in the desert, offering relief from the harsh conditions and aiding in the journey to recovery.

Managing hepatic encephalopathy

This study provides valuable evidence for the potential benefits of LOLA in treating hepatic encephalopathy. It is important to consult with a healthcare professional to determine if LOLA is appropriate for your individual needs.

Dr. Camel's Conclusion

This study offers hope for patients with hepatic encephalopathy, demonstrating the potential of LOLA as a safe and effective adjuvant therapy. It's a reminder that even in the vast and challenging desert of liver disease, we can find oases of relief and hope.
Date :
  1. Date Completed 2012-04-03
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

22078345

DOI: Digital Object Identifier

11.2011/JCPSP.666671

Related Literature

Article Analysis
・Side Effects of lactulose
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.